GLP-1 RA for Stage 1 Type 1 Diabetes

NCT07430332 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 receptor agonist can help preserve insulin production in people recently diagnosed with Stage 1 Type 1 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind prevention study

Participants 15 people Planned (estimated).

Who can join Ages 12–70 · all sexes Healthy volunteers accepted.

Timeline Started 2027-09 · est. completion 2030-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07430332 ↗

Description as written by the study sponsor.

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Treatments tested

Semaglutide Drug

Study participants will be randomized to either placebo or semaglutide treatment for 12 months
Placebo Drug

Randomized to either placebo or semaglutide.

Main thing measured	C-peptide area under the curve
Sponsor	Children's Hospital Medical Center, Cincinnati
Conditions studied	Stage 1 Diabetes Mellitus, Type 1
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07430332 ↗